265 related articles for article (PubMed ID: 33986122)
1. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
[TBL] [Abstract][Full Text] [Related]
2. iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer.
Ding N; Zou Z; Sha H; Su S; Qian H; Meng F; Chen F; Du S; Zhou S; Chen H; Zhang L; Yang J; Wei J; Liu B
Nat Commun; 2019 Mar; 10(1):1336. PubMed ID: 30902997
[TBL] [Abstract][Full Text] [Related]
3. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
[TBL] [Abstract][Full Text] [Related]
4. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
[TBL] [Abstract][Full Text] [Related]
5. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.
Park JA; Santich BH; Xu H; Lum LG; Cheung NV
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986124
[TBL] [Abstract][Full Text] [Related]
6. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
7. Low-dose radiotherapy synergizes with iRGD-antiCD3-modified T cells by facilitating T cell infiltration.
Zhou S; Zhu M; Wei X; Mu P; Shen L; Wang Y; Wan J; Zhang H; Xia F; Zhang Z
Radiother Oncol; 2024 May; 194():110213. PubMed ID: 38458258
[TBL] [Abstract][Full Text] [Related]
8. Lipophilic recombinant-protein insertion endows lymphocytes with enhanced targeting-infiltration ability in EGFR positive cancer.
Du S; Sha H; Ding N; Yang J; Qian H; Zhou S; Su S; Meng F; Chen H; Chen F; Zhang L; Liu B; Wei J
Cell Immunol; 2021 Jul; 365():104376. PubMed ID: 33984534
[TBL] [Abstract][Full Text] [Related]
9. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.
Yang R; Shen S; Gong C; Wang X; Luo F; Luo F; Lei Y; Wang Z; Xu S; Ni Q; Xue Y; Fu Z; Zeng L; Fang L; Yan Y; Zhang J; Gan L; Yi J; Zhou P
Front Immunol; 2021; 12():654080. PubMed ID: 34040604
[TBL] [Abstract][Full Text] [Related]
10. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F
Front Immunol; 2021; 12():719116. PubMed ID: 34484225
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
12. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
[TBL] [Abstract][Full Text] [Related]
13. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.
Malik-Chaudhry HK; Prabhakar K; Ugamraj HS; Boudreau AA; Buelow B; Dang K; Davison LM; Harris KE; Jorgensen B; Ogana H; Pham D; Schellenberger U; Van Schooten W; Buelow R; Iyer S; Trinklein ND; Rangaswamy US
MAbs; 2021; 13(1):1890411. PubMed ID: 33818299
[TBL] [Abstract][Full Text] [Related]
14. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.
Caracciolo D; Riillo C; Ballerini A; Gaipa G; Lhermitte L; Rossi M; Botta C; Duroyon E; Grillone K; Gallo Cantafio ME; Buracchi C; Alampi G; Gulino A; Belmonte B; Conforti F; Golino G; Juli G; Altomare E; Polerà N; Scionti F; Arbitrio M; Iannone M; Martino M; Correale P; Talarico G; Ghelli Luserna di Rorà A; Ferrari A; Concolino D; Sestito S; Pensabene L; Giordano A; Hildinger M; Di Martino MT; Martinelli G; Tripodo C; Asnafi V; Biondi A; Tagliaferri P; Tassone P
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33597219
[TBL] [Abstract][Full Text] [Related]
16. An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy.
Song Y; Xu M; Li Y; Li Y; Gu W; Halimu G; Fu X; Zhang H; Zhang C
Int J Pharm; 2020 Aug; 586():119498. PubMed ID: 32505575
[TBL] [Abstract][Full Text] [Related]
17. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
[TBL] [Abstract][Full Text] [Related]
18. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors.
Yuan Y; Li J; Chen J; Han L; Wang L; Yue Y; Liu J; Zhang B; Yuan Y; Wu M; Bian Y; Xie Y; Zhu J
Biomed Pharmacother; 2024 May; 174():116565. PubMed ID: 38603888
[TBL] [Abstract][Full Text] [Related]
20. Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells.
Zhu M; Wang H; Zhou S; Wei J; Ding N; Shao J; Yu L; Feng Z; Liu B
Onco Targets Ther; 2021; 14():835-844. PubMed ID: 33574677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]